ERBB2 and breast cancer: Previously published data on the use of the radiopharmaceutical[99mTc]Tc-ADAPT6 to determine the HER2/neu status in nALNs of BC patientsdemonstrated its high uptake (SUVmax = 8.7 ± 4.6) and a significantdifference between HER2-positive and HER2-negative foci (p < 0.05, Mann–Whitney test).